{"id":"ty-9591","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL4303550","moleculeType":"Small molecule","molecularWeight":"364.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TY-9591 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"TY-9591 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:44.808Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05146219","phase":"PHASE2","title":"Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2022-04-02","conditions":"NSCLC, EGFR Activating Mutation, Brain Metastases","enrollment":29},{"nctId":"NCT06255951","phase":"PHASE1","title":"Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2024-03-12","conditions":"NSCLC","enrollment":48},{"nctId":"NCT06672068","phase":"PHASE2","title":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","status":"NOT_YET_RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2025-02-20","conditions":"NSCLC","enrollment":60},{"nctId":"NCT05871905","phase":"PHASE1","title":"[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2023-06-19","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT05948813","phase":"PHASE2","title":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","status":"RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2023-08-17","conditions":"NSCLC, EGFR Activating Mutation, Brain Metastases","enrollment":420},{"nctId":"NCT05382728","phase":"PHASE3","title":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","status":"RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2022-06-08","conditions":"NSCLC, EGFR Activating Mutation","enrollment":680},{"nctId":"NCT04204473","phase":"PHASE1","title":"A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2020-05-07","conditions":"NSCLC","enrollment":105},{"nctId":"NCT04798638","phase":"PHASE1","title":"A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2021-04-30","conditions":"Healthy Volunteers","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["C14 TY-9591","TY-9591 Tablets","placebo TY-9591 Tablets"],"phase":"phase_3","status":"active","brandName":"TY-9591","genericName":"TY-9591","companyName":"TYK Medicines, Inc","companyId":"tyk-medicines-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TY-9591 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}